HRP20211970T1 - Policiklički derivati amida kao inhibitori cdk9 - Google Patents
Policiklički derivati amida kao inhibitori cdk9 Download PDFInfo
- Publication number
- HRP20211970T1 HRP20211970T1 HRP20211970TT HRP20211970T HRP20211970T1 HR P20211970 T1 HRP20211970 T1 HR P20211970T1 HR P20211970T T HRP20211970T T HR P20211970TT HR P20211970 T HRP20211970 T HR P20211970T HR P20211970 T1 HRP20211970 T1 HR P20211970T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- use according
- ring
- optionally
- Prior art date
Links
- 101150035324 CDK9 gene Proteins 0.000 title 1
- -1 Polycyclic amide Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- AVIWDYSJSPOOAR-LSDHHAIUSA-N (1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]cyclohexane-1-carboxamide Chemical compound C(C)(=O)N[C@H]1C[C@H](CCC1)C(=O)NC1=NC=C(C(=C1)C1=C2N(N=C1)CC(C2)(C)C)Cl AVIWDYSJSPOOAR-LSDHHAIUSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 102220315634 rs1196125127 Human genes 0.000 claims 1
- 102200160920 rs35304565 Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Spoj formule I za upotrebu u liječenju raka:
[image]
naznačen time što:
A je C(R5) ili N;
R5 je H, C1-3 alkil, CN ili halogen;
R2 je 3-7-eročlani heterocikloalkil ili 3-7-eročlani cikloalkil;
po izboru supstituiran s jednim do tri supstituenta neovisno odabrana iz skupine koju čine R10, OR10, SR10, S(O)R10, S(O)2R10, C(O)R10, C(O)OR10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)H, NHC(O)R10, NR10C(O)H, N R10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NH2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHS(O)2R10, C(O)N R10S(O)2R10, S(O)2NH2, S(O)2NHR10, S(O)2N(R10)2, S(O)2NHC(O)OR10, S(O)2NR10C(O)OR10, C(O)H, C(O)OH, OH, CN, NO2, F, Cl, Br i I; pri čemu se jedna ili više CH2 skupina u prstenu mogu po izboru zamijeniti odgovarajućim brojem -C(O) skupina, jedan ili više atoma sumpora ili dušika u prstenu mogu se po izboru oksidirati tako da tvore S-okside ili N-okside;
R10, pri svakom pojavljivanju, se neovisno bira iz skupine koja sadrži 3 do 6-eročlanu cikloalkilnu ili heterocikloalkilnu skupinu, C1-6 alkil, -O- C1-6 alkil, C1-6 alkil-O- C1-6 alkil, NH2, C(O)NH2, C(O)H, C(O)OH, OH, CN, NO2, F, Cl, Br i I; pri čemu dvije R10 skupine zajedno s atomima na koje su one vezane mogu tvoriti 3 do 6-eročlani cikloalkilnu ili heterocikloalkilnu skupinu; i svaka gore spomenuta R10 alkilna, cikloalkilna i heterocikloalkilna skupina može biti dodatno supstituirana s jednim ili dva supstituenta neovisno odabrana od CN, OH, halogen, C1-3 alkil, -O-C1-3 alkil, NH2, NH- C1-3 alkil, i NHC(O)-C1-3 alkil;
R4 je
[image]
pri čemu X i Y zajedno s atomima na koje su oni vezani, tvore 5 do 7-eročlani heterocikloalkilni prsten koji, osim premoštenog dušika, može sadržavati jedan ili dva heteroatoma odabrana između N, O, i S, koji prsten može biti zasićen ili djelomično zasićen; pri čemu se jedna ili dvije CH2 skupine u prstenu po izboru mogu biti zamijenjene odgovarajućim brojem -C(O) skupina, jedan ili više atoma sumpora ili dušika u prstenu mogu se po izboru oksidirati tako da tvore S-okside ili N-okside i pri čemu prsten može biti supstituiran na ugljiku u prstenu s jednim ili dva supstituenta R10 ili na dušiku u prstenu sa supstituentom R12;
J je N ili CR11; i
R11 je H, C1-3 alkil;
R12 je pri svakom pojavljivanju neovisno odabran iz skupine koja sadrži 3 do 6-eročlanu cikloalkilnu ili heterocikloalkilnu skupinu, C1-6 alkil, C1-6 alkil-O-C1-6 alkil, C(O)NH2, C(O)H; pri čemu R12 alkilna, cikloalkilna i heterocikloalkilna može biti dalje supstituirana s jednim ili dva supstituenta neovisno odabrana između CN, OH, i halogena, C1-3 alkil, NH2, i NH-C1-3 alkil, NHC(O)-C1-3 alkil, ili njihove farmaceutski prihvatljive soli;
nadalje pri čemu je rak hematološki malignitet odabran između akutne mijeloične leukemije, multiplog mijeloma, kronične limfocitne leukemije, difuznog limfoma velikih B stanica, Burkittovog limfoma, folikularnog limfoma ili solidnog tumora odabranog između raka dojke, raka pluća, neuroblastoma i raka debelog crijeva.
2. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što je rak hematološki malignitet odabran između akutne mijeloične leukemije, multiplog mijeloma, kronične limfocitne leukemije, difuznog limfoma velikih B stanica, Burkittovog limfoma i folikularnog limfoma.
3. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što je rak akutna mijeloična leukemija.
4. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što je rak difuzni limfom velikih B stanica.
5. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što A je C(R5).
6. Spoj za upotrebu prema patentnom zahtjevu 5 naznačen time što R5 je klor ili fluor.
7. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što R2 je 3-7-eročlani cikloalkil, po izboru supstituiran s NHCOR10 ili R10.
8. Spoj za upotrebu prema patentnom zahtjevu 7 naznačen time što je R2 odabran iz skupa koji sadrži ciklopropil, ciklobutil, ciklopentil, cikloheksil, i cikloheptil.
9. Spoj za upotrebu prema patentnom zahtjevu 8 naznačen time što je R2 ciklopentil ili cikloheksil.
10. Spoj za upotrebu prema patentnom zahtjevu 9 naznačen time što je R2 cikloheksil supstituiran s NHCOR10.
11. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što R2 je 3-7-eročlani heterocikloalkil, po izboru pri čemu je R2 supstituiran s NHCOR10.
12. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što X i Y zajedno s atomima na koje su oni vezani tvore 6-eročlani heterocikloalkil prsten, po izboru pri čemu 6-eročlani heterocikloalkilni prsten sadrži dodatni heteroatom koji je kisik ili dušik.
13. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što X i Y zajedno s atomima na koje su oni vezani tvore 5-eročlani heterocikloalkil prsten, po izboru pri čemu je jedan CH2 u 5-eročlanom heterocikloalkilnom prstenu supstituiran s dvije metilne skupine.
14. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što X i Y zajedno s atomima na koje su oni vezani tvore 7-eročlani heterocikloalkilni prsten.
15. Spoj za upotrebu prema patentnom zahtjevu 1 naznačen time što je (1S,3R)-3-acetamido-N-(5-kloro-4-(5,5-dimetil-5,6-dihidro-4H-pirolo[1,2-b]pirazol-3-il)piridin-2-il)cikloheksankarboksamid, ili njegova farmaceutski prihvatljiva sol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| EP19165726.1A EP3539961B1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211970T1 true HRP20211970T1 (hr) | 2022-03-18 |
Family
ID=56292699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211970TT HRP20211970T1 (hr) | 2015-06-29 | 2016-06-27 | Policiklički derivati amida kao inhibitori cdk9 |
| HRP20190748TT HRP20190748T1 (hr) | 2015-06-29 | 2019-04-19 | Derivati policikličkog amida kao inhibitori cdk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190748TT HRP20190748T1 (hr) | 2015-06-29 | 2019-04-19 | Derivati policikličkog amida kao inhibitori cdk9 |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (hr) |
| EP (2) | EP3539961B1 (hr) |
| JP (1) | JP6997627B2 (hr) |
| KR (1) | KR102663113B1 (hr) |
| CN (1) | CN107873028B (hr) |
| AR (1) | AR105179A1 (hr) |
| AU (1) | AU2016286200B2 (hr) |
| BR (1) | BR122019013677B1 (hr) |
| CA (1) | CA2989499C (hr) |
| CL (1) | CL2017003306A1 (hr) |
| CO (1) | CO2017013713A2 (hr) |
| CR (2) | CR20210297A (hr) |
| CY (2) | CY1122111T1 (hr) |
| DK (2) | DK3539961T3 (hr) |
| DO (2) | DOP2017000295A (hr) |
| EA (1) | EA035383B1 (hr) |
| ES (2) | ES2728356T3 (hr) |
| HR (2) | HRP20211970T1 (hr) |
| HU (2) | HUE057343T2 (hr) |
| IL (1) | IL256393B (hr) |
| LT (2) | LT3539961T (hr) |
| ME (1) | ME03404B (hr) |
| MX (1) | MX371034B (hr) |
| NI (1) | NI201700174A (hr) |
| PE (1) | PE20180530A1 (hr) |
| PH (1) | PH12017502334A1 (hr) |
| PL (2) | PL3313838T3 (hr) |
| PT (2) | PT3539961T (hr) |
| RS (2) | RS62781B1 (hr) |
| SI (2) | SI3313838T1 (hr) |
| SV (1) | SV2017005598A (hr) |
| TN (1) | TN2017000486A1 (hr) |
| TR (1) | TR201909286T4 (hr) |
| TW (1) | TWI723028B (hr) |
| WO (1) | WO2017001354A1 (hr) |
| ZA (1) | ZA201800563B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200058462A (ko) | 2017-09-25 | 2020-05-27 | 아스트라제네카 아베 | 암을 치료하기 위한 btk 억제제 및 cdk9의 억제제의 조합 |
| WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2020259556A1 (zh) * | 2019-06-27 | 2020-12-30 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| JP2022548568A (ja) * | 2019-09-11 | 2022-11-21 | プレリュード・セラピューティクス・インコーポレイテッド | Ｃｄｋ阻害剤及び医薬品としてのそれらの使用 |
| CA3161351A1 (en) * | 2019-12-09 | 2021-06-17 | Zhenyu Wang | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| CN113149996B (zh) * | 2020-05-12 | 2022-12-20 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| JP7451765B2 (ja) * | 2020-05-12 | 2024-03-18 | 蘇州阿尓脈生物科技有限公司 | Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途 |
| US20230233540A1 (en) | 2020-06-24 | 2023-07-27 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
| US20230271942A1 (en) | 2020-08-07 | 2023-08-31 | Pharmablock Sciences (Nanjing), Inc. | Cdk9 inhibitor and use thereof |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381823A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| KR20240137563A (ko) * | 2021-12-23 | 2024-09-20 | 카톨리에케 유니버시테이트 루벤 | Yap/taz-tead 억제를 위한 테트라히드로피라졸로피리미딘 및 관련 유사체 |
| WO2024039210A1 (ko) | 2022-08-17 | 2024-02-22 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| JP5681855B2 (ja) | 2007-10-12 | 2015-03-11 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
| AU2010291212A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) * | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| NZ601924A (en) | 2010-03-10 | 2014-10-31 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| RU2627272C2 (ru) * | 2011-10-06 | 2017-08-04 | Байер Интеллектчуал Проперти Гмбх | Гетероциклилпиридинилпиразолы |
| WO2014160017A1 (en) * | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| CN105026393A (zh) | 2013-03-13 | 2015-11-04 | 艾伯维公司 | Cdk9激酶抑制剂 |
| WO2014151444A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| CN105189512A (zh) | 2013-03-14 | 2015-12-23 | 艾伯维公司 | 吡咯并嘧啶cdk9激酶抑制剂 |
-
2016
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active IP Right Grant
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211970T1 (hr) | Policiklički derivati amida kao inhibitori cdk9 | |
| EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
| CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| JP2019510798A5 (hr) | ||
| GEP20186840B (en) | Pyrrolo [2,3-d] pyrimidinyl, pyrrolo [2,3-b] pyrazinyl and pyrrolo [2,3-d] pyridinyl acrylamides | |
| HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| RU2018101897A (ru) | Бициклическое гетероциклическое амидное производное | |
| EA201391324A1 (ru) | Бис(фторалкил)-1,4-бензодиазепиноновые соединения | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| HRP20221207T1 (hr) | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| GEP201606540B (en) | New indolizine derivatives, method for their preparation and pharmaceutical compositions containing thereof | |
| JP2016501185A5 (hr) | ||
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| HRP20190814T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe | |
| EA201790713A1 (ru) | N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения |